Barclays
KTTA icon

Barclays’s Pasithea Therapeutics KTTA Stock Holding History

Barclays’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139 Buy
+269
New +$185 ﹤0.01% 5158

Other funds holding KTTA

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Barclays's KTTA Position: Q2 2026 in Review

Barclays opened a new position in Pasithea Therapeutics (KTTA) in Q2 2026: 269 shares worth $139. The stake represents ﹤0.01% of the portfolio and ranks #5158 among its holdings.

25 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • Barclays held 269 shares of Pasithea Therapeutics worth $139 as of Q2 2026.
  • Pasithea Therapeutics was a new Barclays position in Q2 2026.
  • Pasithea Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5158 holding.
  • 25 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.